Alliances and Collaborations
Strategic alliances and commercialization agreements aim to provide space for innovative solutions to accelerate breakthrough discoveries in cancer research while developing deeper relationships with companies that share a similar vision. This can be done through joint development opportunities, collaborations, licensing or a combination of these elements.
Strategic alliances and commercialization agreements aim to provide space for innovative solutions to accelerate breakthrough discoveries in cancer research while developing deeper relationships with companies that share a similar vision. This can be done through joint development opportunities, collaborations, licensing or a combination of these elements.
UT MD Anderson and Blue Print Medicines announced strategic collaboration to accelerate development of BLU-222, an investigational precision therapy designed to target cyclin-dependent kinase 2 (CDK2).
UT MD Anderson and Empyrean announced agreement to develop novel radiation therapy technologies.
UT MD Anderson and Radiopharm Theranostics launched Radiopharm Ventures, LLC, a joint venture created to develop novel radiopharmaceutical therapeutic products for cancer.
UT MD Anderson and Taiho Pharmaceutical announced a collaboration to accelerate development of novel therapies for brain metastasis and other unmet needs.
UT MD Anderson and Boehringer Ingelheim expanded collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer.
Genentech
UT MD Anderson and Genentech launched and expanded strategic alliance consisting of preclinical and clinical studies.
UT MD Anderson and Siemens Healthineers collaborated to enable consistent clinical implementation of quantitative MRI.
UT MD Anderson and TriSalus Life Sciences announced strategic research collaboration to evaluate treatment of solid tumors
UT MD Anderson, Invectys and CTMC announced strategic collaboration for CAR T cell therapy development.
Immatics and UT MD Anderson announced launch of Immatics US, Inc., to develop multiple T cell and TCR-based adoptive cellular therapies.
UT MD Anderson and Spectrum Pharmaceuticals signed a licensing agreement that covers discoveries by UT MD Anderson researchers about the company's drug Poziotinib, a targeted therapy for lung cancer.
UT MD Anderson and Varian partnered to optimize radiation oncology treatment.
Note: This is not a comprehensive list of all active strategic and commercialization partners of UT MD Anderson.
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.